3 results
Assess cognitive efficacy of gantenerumab, solanezumab in individuals who have mutations causing dominantly inherited Alzheimer's disease as measured by change in the DIAN-TU cognitive composite score between baseline and a minimum of 4 years.…
Primary objective: To assess the effect of transdermal GTN, started within 3 hours of symptom onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.Secondary…
To develop an exergame system which helps patients, ICU staff (including physiotherapists), in ameliorating early mobilisation exercises (frequency, intensity and patient and staff experience), finally aiming to accelerated rehabilitation and reduce…